CorMatrix wins FDA nod for tricuspid valve trial

CorMatrix Cardiovascular wins an investigational device exemption from the FDA for a small feasibility study of its new tricuspid valve replacement.

Georgia's CorMatrix Cardiovascular said this week that it plans to enroll up to 15 pediatric and adult patients in a feasibility study of its new tricuspid valve replacement device.

CorMatrix Cardiovascular Inc., Food & Drug Administration (FDA)

News Well, Clinical Trials, Pediatrics, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1B2ro3K